Elan（25E）株式概要エラン・コーポレーションは主に日本で介護事業を行っている。 詳細25E ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長2/6過去の実績5/6財務の健全性5/6配当金3/6報酬当社が推定した公正価値より48.2%で取引されている 収益は年間12.47%増加すると予測されています 過去1年間で収益は20.2%増加しました リスク分析リスクチェックの結果、25E 、リスクは検出されなかった。すべてのリスクチェックを見る25E Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW476,058 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA476,058 investors already sharing narrativesYour Fair Value€Current Price€3.9823.6% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture093b2016201920222025202620282031Revenue JP¥93.4bEarnings JP¥4.8bAdvancedSet Fair ValueView all narrativesElan Corporation 競合他社MediosSymbol: XTRA:ILM1Market cap: €271.5mM1 KlinikenSymbol: XTRA:M12Market cap: €351.1mLIMES SchlossklinikenSymbol: XTRA:LIKMarket cap: €169.8mMEDICLINSymbol: XTRA:MEDMarket cap: €194.8m価格と性能株価の高値、安値、推移の概要Elan過去の株価現在の株価JP¥3.9852週高値JP¥5.0052週安値JP¥3.40ベータ0.641ヶ月の変化3.65%3ヶ月変化7.57%1年変化-17.77%3年間の変化-25.61%5年間の変化-55.03%IPOからの変化231.17%最新ニュースBoard Change • May 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Outside Director Masaru Miura was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.お知らせ • Feb 04Elan Corporation, Annual General Meeting, Mar 25, 2026Elan Corporation, Annual General Meeting, Mar 25, 2026.お知らせ • Dec 03+ 3 more updatesElan Corporation to Report Fiscal Year 2025 Results on Feb 04, 2026Elan Corporation announced that they will report fiscal year 2025 results on Feb 04, 2026お知らせ • Mar 01+ 2 more updatesElan Corporation to Report Q3, 2025 Results on Nov 07, 2025Elan Corporation announced that they will report Q3, 2025 results on Nov 07, 2025お知らせ • Feb 10Elan Corporation, Annual General Meeting, Mar 21, 2025Elan Corporation, Annual General Meeting, Mar 21, 2025.お知らせ • Jan 21Elan Corporation (TSE:6099) completed the acquisition of 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others.Elan Corporation (TSE:6099) agreed to acquire 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others for VND 180 billion on March 22, 2024. For the period ended December 31, 2023, Tmc Viet Nam Trading reported revenue of VND 150 billion, total assets of VND 210 billion, operating income of VND 6 billion, net income of 2.3 billion and net assets of 57 billion. The transaction has been approved by the board of directors of Elan Corporation. The transaction is expected to close in mid June 2024. As of January 20, 2025, the transaction is expected to close in January 2025. Elan Corporation (TSE:6099) completed the acquisition of 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others on January 21, 2025.最新情報をもっと見るRecent updatesBoard Change • May 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Outside Director Masaru Miura was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.お知らせ • Feb 04Elan Corporation, Annual General Meeting, Mar 25, 2026Elan Corporation, Annual General Meeting, Mar 25, 2026.お知らせ • Dec 03+ 3 more updatesElan Corporation to Report Fiscal Year 2025 Results on Feb 04, 2026Elan Corporation announced that they will report fiscal year 2025 results on Feb 04, 2026お知らせ • Mar 01+ 2 more updatesElan Corporation to Report Q3, 2025 Results on Nov 07, 2025Elan Corporation announced that they will report Q3, 2025 results on Nov 07, 2025お知らせ • Feb 10Elan Corporation, Annual General Meeting, Mar 21, 2025Elan Corporation, Annual General Meeting, Mar 21, 2025.お知らせ • Jan 21Elan Corporation (TSE:6099) completed the acquisition of 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others.Elan Corporation (TSE:6099) agreed to acquire 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others for VND 180 billion on March 22, 2024. For the period ended December 31, 2023, Tmc Viet Nam Trading reported revenue of VND 150 billion, total assets of VND 210 billion, operating income of VND 6 billion, net income of 2.3 billion and net assets of 57 billion. The transaction has been approved by the board of directors of Elan Corporation. The transaction is expected to close in mid June 2024. As of January 20, 2025, the transaction is expected to close in January 2025. Elan Corporation (TSE:6099) completed the acquisition of 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others on January 21, 2025.お知らせ • Dec 14ELAN Corporation Announces CEO Changes, Effective March 21, 2025ELAN Corporation announced that it has resolved, at a meeting of the Board of Directors held on December 13, 2024, to change the Company's CEO. Hideharu Sakurai is scheduled to retire as CEO and Tomohiro Minezaki, the current COO, will succeed him as CEO. Scheduled date of assuming office is March 21, 2025.お知らせ • Dec 10Elan Corporation to Report Fiscal Year 2024 Results on Feb 10, 2025Elan Corporation announced that they will report fiscal year 2024 results on Feb 10, 2025Reported Earnings • Nov 08Third quarter 2024 earnings released: EPS: JP¥8.39 (vs JP¥10.50 in 3Q 2023)Third quarter 2024 results: EPS: JP¥8.39 (down from JP¥10.50 in 3Q 2023). Revenue: JP¥12.0b (up 13% from 3Q 2023). Net income: JP¥507.2m (down 20% from 3Q 2023). Profit margin: 4.2% (down from 6.0% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Sep 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €5.95, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 14x in the Healthcare industry in Germany. Total loss to shareholders of 36% over the past three years.Reported Earnings • Aug 09Second quarter 2024 earnings released: EPS: JP¥9.91 (vs JP¥9.23 in 2Q 2023)Second quarter 2024 results: EPS: JP¥9.91 (up from JP¥9.23 in 2Q 2023). Revenue: JP¥11.4b (up 14% from 2Q 2023). Net income: JP¥599.0m (up 7.3% from 2Q 2023). Profit margin: 5.3% (down from 5.6% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Declared Dividend • Aug 08Dividend of JP¥14.00 announcedShareholders will receive a dividend of JP¥14.00. Ex-date: 27th December 2024 Payment date: 25th March 2025 Dividend yield will be 290%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is covered by both earnings (31% earnings payout ratio) and cash flows (53% cash payout ratio). The dividend has increased by an average of 32% per year over the past 7 years and payments have been stable during that time. EPS is expected to grow by 67% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Jun 02Elan Corporation to Report Q2, 2024 Results on Aug 06, 2024Elan Corporation announced that they will report Q2, 2024 results on Aug 06, 2024Reported Earnings • May 09First quarter 2024 earnings released: EPS: JP¥12.01 (vs JP¥11.50 in 1Q 2023)First quarter 2024 results: EPS: JP¥12.01 (up from JP¥11.50 in 1Q 2023). Revenue: JP¥11.5b (up 17% from 1Q 2023). Net income: JP¥726.0m (up 4.5% from 1Q 2023). Profit margin: 6.3% (down from 7.1% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 27Full year 2023 earnings released: EPS: JP¥41.65 (vs JP¥34.44 in FY 2022)Full year 2023 results: EPS: JP¥41.65 (up from JP¥34.44 in FY 2022). Revenue: JP¥41.4b (up 14% from FY 2022). Net income: JP¥2.52b (up 21% from FY 2022). Profit margin: 6.1% (up from 5.7% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.お知らせ • Mar 22Elan Corporation (TSE:6099) agreed to acquire 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others for VND220 billion.Elan Corporation (TSE:6099) agreed to acquire 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others for VND220 billion on March 22, 2024. The transaction is expected to close in mid June 2024.お知らせ • Feb 24Elan Corporation to Report Q1, 2024 Results on May 08, 2024Elan Corporation announced that they will report Q1, 2024 results on May 08, 2024Reported Earnings • Feb 16Full year 2023 earnings released: EPS: JP¥41.65 (vs JP¥34.44 in FY 2022)Full year 2023 results: EPS: JP¥41.65 (up from JP¥34.44 in FY 2022). Revenue: JP¥41.4b (up 14% from FY 2022). Net income: JP¥2.52b (up 21% from FY 2022). Profit margin: 6.1% (up from 5.7% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.お知らせ • Feb 15Elan Corporation, Annual General Meeting, Mar 22, 2024Elan Corporation, Annual General Meeting, Mar 22, 2024.Upcoming Dividend • Dec 21Upcoming dividend of JP¥12.00 per share at 1.1% yieldEligible shareholders must have bought the stock before 28 December 2023. Payment date: 27 March 2024. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (3.2%).お知らせ • Dec 05Elan Corporation to Report Fiscal Year 2023 Results on Feb 14, 2024Elan Corporation announced that they will report fiscal year 2023 results on Feb 14, 2024Reported Earnings • Nov 08Third quarter 2023 earnings released: EPS: JP¥10.50 (vs JP¥9.69 in 3Q 2022)Third quarter 2023 results: EPS: JP¥10.50 (up from JP¥9.69 in 3Q 2022). Revenue: JP¥10.6b (up 16% from 3Q 2022). Net income: JP¥635.0m (up 8.4% from 3Q 2022). Profit margin: 6.0% (down from 6.4% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 1.3% decline forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.お知らせ • Aug 30Elan Corporation to Report Q3, 2023 Results on Nov 07, 2023Elan Corporation announced that they will report Q3, 2023 results on Nov 07, 2023New Risk • Aug 11New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.お知らせ • Aug 09Elan Corporation Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2023Elan Corporation provided consolidated earnings guidance for the full year ending December 31, 2023. For the year, the company expects net sales of ¥43,700 million, operating profit of ¥3,600 million, profit attributable to owners of parent of ¥2,500 million, and earnings per share of ¥41.35.Reported Earnings • Aug 08Second quarter 2023 earnings released: EPS: JP¥9.23 (vs JP¥9.11 in 2Q 2022)Second quarter 2023 results: EPS: JP¥9.23 (up from JP¥9.11 in 2Q 2022). Revenue: JP¥9.92b (up 13% from 2Q 2022). Net income: JP¥558.0m (up 1.3% from 2Q 2022). Profit margin: 5.6% (down from 6.3% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Jun 28Elan Corporation to Report Q2, 2023 Results on Aug 07, 2023Elan Corporation announced that they will report Q2, 2023 results on Aug 07, 2023Reported Earnings • May 12First quarter 2023 earnings released: EPS: JP¥11.50 (vs JP¥10.35 in 1Q 2022)First quarter 2023 results: EPS: JP¥11.50 (up from JP¥10.35 in 1Q 2022). Revenue: JP¥9.86b (up 12% from 1Q 2022). Net income: JP¥695.0m (up 11% from 1Q 2022). Profit margin: 7.1% (in line with 1Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • May 12+ 1 more updateElan Corporation Provides Consolidated Earnings Guidance for the Six Month Ending June 30, 2023 and Full Year Ending December 31, 2023Elan Corporation provided consolidated earnings guidance for the six month ending June 30, 2023 and full year ending December 31, 2023. For the six months, the company expects net sales of ¥20,300 million, operating profit of ¥1,730 million, profit attributable to owners of parent of ¥1,200 million, and earnings per share of ¥19.85.For the year, the company expects net sales of ¥43,700 million, operating profit of ¥3,600 million, profit attributable to owners of parent of ¥2,500 million, and earnings per share of ¥41.35.Reported Earnings • Mar 30Full year 2022 earnings released: EPS: JP¥34.44 (vs JP¥31.48 in FY 2021)Full year 2022 results: EPS: JP¥34.44 (up from JP¥31.48 in FY 2021). Revenue: JP¥36.3b (up 15% from FY 2021). Net income: JP¥2.08b (up 9.3% from FY 2021). Profit margin: 5.7% (down from 6.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 12Full year 2022 earnings released: EPS: JP¥34.44 (vs JP¥31.48 in FY 2021)Full year 2022 results: EPS: JP¥34.44 (up from JP¥31.48 in FY 2021). Revenue: JP¥36.3b (up 15% from FY 2021). Net income: JP¥2.08b (up 9.3% from FY 2021). Profit margin: 5.7% (down from 6.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Feb 10+ 2 more updatesElan Corporation, Annual General Meeting, Mar 24, 2023Elan Corporation, Annual General Meeting, Mar 24, 2023.お知らせ • Dec 28Elan Corporation to Report Fiscal Year 2022 Results on Feb 09, 2023Elan Corporation announced that they will report fiscal year 2022 results on Feb 09, 2023Upcoming Dividend • Dec 22Upcoming dividend of JP¥10.00 per shareEligible shareholders must have bought the stock before 29 December 2022. Payment date: 24 March 2023. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (4.0%).Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 7 non-independent directors. Outside Independent Director Nobuyuki Takagi was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Nov 12Third quarter 2022 earnings released: EPS: JP¥9.69 (vs JP¥8.70 in 3Q 2021)Third quarter 2022 results: EPS: JP¥9.69 (up from JP¥8.70 in 3Q 2021). Revenue: JP¥9.16b (up 14% from 3Q 2021). Net income: JP¥586.0m (up 11% from 3Q 2021). Profit margin: 6.4% (down from 6.5% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 12+ 1 more updateElan Corporation Provides Consolidated Earning Guidance for the Year Ending December 31, 2022Elan Corporation provided consolidated earning guidance for the year ending December 31, 2022. For the period, the company expected net sales to be JPY 37,000 million, operating profit to be JPY 3,000 million, ordinary profit to be JPY 3,020 million, profit attributable to owners of parent to be JPY 2,000 million and earnings per share to be JPY 33.08.お知らせ • Aug 31Elan Corporation to Report Q3, 2022 Results on Nov 10, 2022Elan Corporation announced that they will report Q3, 2022 results on Nov 10, 2022お知らせ • Aug 16+ 1 more updateElan Corporation Provides Earnings Guidance for the Year Ending December 31, 2022Elan Corporation provided earning guidance for the year ending December 31, 2022. For the period, the company expects net sales of JPY 37,000 million, operating profit of JPY 3,000 million, ordinary profit of JPY 3,020 million, profit attributable to owners of parent of JPY 2,000 million and earnings per share JPY 33.08.Reported Earnings • Aug 12Second quarter 2022 earnings released: EPS: JP¥9.11 (vs JP¥7.42 in 2Q 2021)Second quarter 2022 results: EPS: JP¥9.11 (up from JP¥7.42 in 2Q 2021). Revenue: JP¥8.81b (up 14% from 2Q 2021). Net income: JP¥551.0m (up 23% from 2Q 2021). Profit margin: 6.3% (up from 5.8% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 2.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.お知らせ • May 29Elan Corporation to Report Q2, 2022 Results on Aug 10, 2022Elan Corporation announced that they will report Q2, 2022 results on Aug 10, 2022お知らせ • May 16+ 1 more updateElan Corporation Provides Dividend Guidance for the Year Ending December 31, 2022Elan Corporation provided dividend guidance for the year ending December 31, 2022. For the year, the company expects to pay dividend of JPY 10.00 per share.Reported Earnings • May 15First quarter 2022 earnings released: EPS: JP¥10.35 (vs JP¥8.37 in 1Q 2021)First quarter 2022 results: EPS: JP¥10.35 (up from JP¥8.37 in 1Q 2021). Revenue: JP¥8.79b (up 17% from 1Q 2021). Net income: JP¥626.0m (up 24% from 1Q 2021). Profit margin: 7.1% (up from 6.7% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 16%, compared to a 5.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Board Change • Apr 28No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 5 highly experienced directors. No independent directors (8 non-independent directors). VP & Director Yoshiteru Ando was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 08Elan Corporation to Report Q1, 2022 Results on May 12, 2022Elan Corporation announced that they will report Q1, 2022 results on May 12, 2022お知らせ • Feb 16Elan Corporation Provides Consolidated Earnings Guidance for the Six Months Ending June 30, 2022 and Year Ending December 31, 2022Elan Corporation provided consolidated earnings guidance for the six months ending June 30, 2022 and Year Ending December 31, 2022. For the period, the company expects net sales of JPY 17,300 million, operating profit of JPY 1,430 million, profit attributable to owners of parent of JPY 980 million and earnings per share of JPY 16.21.For the year, the company expects net sales of JPY 37,000 million, operating profit of JPY 3,000 million, profit attributable to owners of parent of JPY 2,000 million and earnings per share of JPY 33.08.お知らせ • Feb 15+ 1 more updateElan Corporation Announces Dividend for the Year Ended December 31, 2021, Payable on March 24, 2022Elan Corporation announced dividend for the year ended December 31, 2021. For the year, the company announced to pay dividend of JPY 9.00 per share compared to JPY 14 per share paid a year ago. Scheduled date to commence dividend payments: March 24, 2022.お知らせ • Feb 12Elan Corporation, Annual General Meeting, Mar 23, 2022Elan Corporation, Annual General Meeting, Mar 23, 2022.Reported Earnings • Feb 11Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: JP¥31.48 (up from JP¥23.86 in FY 2020). Revenue: JP¥31.6b (up 21% from FY 2020). Net income: JP¥1.91b (up 32% from FY 2020). Profit margin: 6.0% (up from 5.5% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 19%, compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.Buying Opportunity • Jan 17Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 17%. The fair value is estimated to be JP¥9.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% per annum over the last 3 years. Earnings per share has grown by 28% per annum over the last 3 years.Upcoming Dividend • Dec 22Upcoming dividend of JP¥8.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 24 March 2022. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (2.6%).Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS JP¥8.70 (vs JP¥6.24 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥8.06b (up 21% from 3Q 2020). Net income: JP¥526.0m (up 39% from 3Q 2020). Profit margin: 6.5% (up from 5.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 13Elan Corporation Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021Elan Corporation provided consolidated earnings guidance for the year ending December 31, 2021. For the year, the company expects net sales of JPY 31,000 million, operating profit of JPY 2,500 million, profit attributable to owners of parent of JPY 1,680 million and earnings per share of JPY 27.72.お知らせ • May 17+ 1 more updateElan Corporation Provides Earnings Guidance for the Six Months and Year Ending December 31, 2021Elan Corporation provided earnings guidance for the six months and year ending December 31, 2021. For the six months, the company expected Net sales of JPY 15,100 Million, Operating profit of JPY 1,300 Million, Profit attributable to owners of parent of JPY 900 Million and Earnings per share of JPY 14.85. For the year, the company expected Net sales of JPY 31,000 Million, Operating profit of JPY 2,500 Million, Profit attributable to owners of parent of JPY 1,680 Million and Earnings per share of JPY 27.72.Reported Earnings • May 15First quarter 2021 earnings released: EPS JP¥8.37 (vs JP¥5.61 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: JP¥7.52b (up 26% from 1Q 2020). Net income: JP¥507.0m (up 49% from 1Q 2020). Profit margin: 6.7% (up from 5.7% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Mar 30Full year 2020 earnings released: EPS JP¥47.72 (vs JP¥16.32 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: JP¥26.1b (up 21% from FY 2019). Net income: JP¥1.45b (up 46% from FY 2019). Profit margin: 5.5% (up from 4.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year whereas the company’s share price has increased by 40% per year.Is New 90 Day High Low • Feb 20New 90-day low: €10.60The company is down 11% from its price of €11.90 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.35 per share.お知らせ • Feb 14Elan Corporation, Annual General Meeting, Mar 23, 2021Elan Corporation, Annual General Meeting, Mar 23, 2021.Reported Earnings • Feb 14Full year 2020 earnings released: EPS JP¥47.72 (vs JP¥16.32 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: JP¥26.1b (up 21% from FY 2019). Net income: JP¥1.45b (up 46% from FY 2019). Profit margin: 5.5% (up from 4.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.Analyst Estimate Surprise Post Earnings • Feb 14Revenue beats expectationsRevenue exceeded analyst estimates by 3.0%. Over the next year, revenue is forecast to grow 14%, compared to a 3.4% growth forecast for the Healthcare industry in Germany.お知らせ • Jan 07Elan Corporation to Report Fiscal Year 2020 Results on Feb 12, 2021Elan Corporation announced that they will report fiscal year 2020 results on Feb 12, 2021Upcoming Dividend • Dec 22Upcoming Dividend of JP¥12.00 Per ShareWill be paid on the 26th of March to those who are registered shareholders by the 29th of December. The trailing yield of 0.4% is below the top quartile of German dividend payers (3.5%), and is lower than industry peers (2.1%).Reported Earnings • Nov 19Third quarter 2020 earnings released: EPS JP¥12.48The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: JP¥6.69b (up 23% from 3Q 2019). Net income: JP¥378.0m (up 62% from 3Q 2019). Profit margin: 5.6% (up from 4.3% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.Analyst Estimate Surprise Post Earnings • Nov 19Revenue beats expectationsRevenue exceeded analyst estimates by 6.2%. Over the next year, revenue is forecast to grow 14%, compared to a 4.2% growth forecast for the Healthcare industry in Germany.Is New 90 Day High Low • Nov 16New 90-day high: €22.60The company is up 21% from its price of €18.70 on 18 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.46 per share.Analyst Estimate Surprise Post Earnings • Nov 14Revenue beats expectationsRevenue exceeded analyst estimates by 6.2%. Over the next year, revenue is forecast to grow 13%, compared to a 4.3% growth forecast for the Healthcare industry in Germany.Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS JP¥12.48The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: JP¥6.69b (up 23% from 3Q 2019). Net income: JP¥378.0m (up 62% from 3Q 2019). Profit margin: 5.6% (up from 4.3% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Sep 28New 90-day high: €20.60The company is up 35% from its price of €15.30 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.13 per share.お知らせ • Sep 11Elan Corporation to Report Q3, 2020 Results on Nov 12, 2020Elan Corporation announced that they will report Q3, 2020 results on Nov 12, 2020株主還元25EDE HealthcareDE 市場7D1.5%4.0%3.0%1Y-17.8%5.0%1.8%株主還元を見る業界別リターン: 25E過去 1 年間で5 % の収益を上げたGerman Healthcare業界を下回りました。リターン対市場: 25Eは、過去 1 年間で1.8 % のリターンを上げたGerman市場を下回りました。価格変動Is 25E's price volatile compared to industry and market?25E volatility25E Average Weekly Movement4.1%Healthcare Industry Average Movement5.7%Market Average Movement5.4%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.7%安定した株価: 25E 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 25Eの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1995974Tomohiro Minezakiwww.kkelan.com株式会社エランは主に日本で介護事業を行っている。入院患者や老人ホーム入居者向けに、衣類やタオル、おむつなどの日用品の洗濯サービス付きレンタルサービスを提供している。また、入院保証サービス、入退院に特化したコンサルティングサービス、介護用品の通販サイト「エランオンラインショップ」の運営も行っている。エランコーポレーションは1995年に設立され、松本市に本社を置く。2024年10月21日現在、株式会社エムスリーの子会社として運営されている。もっと見るElan Corporation 基礎のまとめElan の収益と売上を時価総額と比較するとどうか。25E 基礎統計学時価総額€256.45m収益（TTM）€15.88m売上高(TTM)€309.04m16.1xPER（株価収益率0.8xP/Sレシオ25E は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計25E 損益計算書（TTM）収益JP¥56.78b売上原価JP¥44.50b売上総利益JP¥12.28bその他の費用JP¥9.36b収益JP¥2.92b直近の収益報告Mar 31, 2026次回決算日Jul 31, 2026一株当たり利益（EPS）48.24グロス・マージン21.63%純利益率5.14%有利子負債／自己資本比率4.6%25E の長期的なパフォーマンスは？過去の実績と比較を見る配当金2.1%現在の配当利回り31%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/30 14:51終値2026/07/30 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Elan Corporation 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Hiroyuki TeradaHaitong International Research LimitedMasatoshi NagataIchiyoshi Research Institute Inc.null nullStorm Research Limited
Board Change • May 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Outside Director Masaru Miura was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
お知らせ • Feb 04Elan Corporation, Annual General Meeting, Mar 25, 2026Elan Corporation, Annual General Meeting, Mar 25, 2026.
お知らせ • Dec 03+ 3 more updatesElan Corporation to Report Fiscal Year 2025 Results on Feb 04, 2026Elan Corporation announced that they will report fiscal year 2025 results on Feb 04, 2026
お知らせ • Mar 01+ 2 more updatesElan Corporation to Report Q3, 2025 Results on Nov 07, 2025Elan Corporation announced that they will report Q3, 2025 results on Nov 07, 2025
お知らせ • Feb 10Elan Corporation, Annual General Meeting, Mar 21, 2025Elan Corporation, Annual General Meeting, Mar 21, 2025.
お知らせ • Jan 21Elan Corporation (TSE:6099) completed the acquisition of 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others.Elan Corporation (TSE:6099) agreed to acquire 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others for VND 180 billion on March 22, 2024. For the period ended December 31, 2023, Tmc Viet Nam Trading reported revenue of VND 150 billion, total assets of VND 210 billion, operating income of VND 6 billion, net income of 2.3 billion and net assets of 57 billion. The transaction has been approved by the board of directors of Elan Corporation. The transaction is expected to close in mid June 2024. As of January 20, 2025, the transaction is expected to close in January 2025. Elan Corporation (TSE:6099) completed the acquisition of 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others on January 21, 2025.
Board Change • May 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Outside Director Masaru Miura was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
お知らせ • Feb 04Elan Corporation, Annual General Meeting, Mar 25, 2026Elan Corporation, Annual General Meeting, Mar 25, 2026.
お知らせ • Dec 03+ 3 more updatesElan Corporation to Report Fiscal Year 2025 Results on Feb 04, 2026Elan Corporation announced that they will report fiscal year 2025 results on Feb 04, 2026
お知らせ • Mar 01+ 2 more updatesElan Corporation to Report Q3, 2025 Results on Nov 07, 2025Elan Corporation announced that they will report Q3, 2025 results on Nov 07, 2025
お知らせ • Feb 10Elan Corporation, Annual General Meeting, Mar 21, 2025Elan Corporation, Annual General Meeting, Mar 21, 2025.
お知らせ • Jan 21Elan Corporation (TSE:6099) completed the acquisition of 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others.Elan Corporation (TSE:6099) agreed to acquire 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others for VND 180 billion on March 22, 2024. For the period ended December 31, 2023, Tmc Viet Nam Trading reported revenue of VND 150 billion, total assets of VND 210 billion, operating income of VND 6 billion, net income of 2.3 billion and net assets of 57 billion. The transaction has been approved by the board of directors of Elan Corporation. The transaction is expected to close in mid June 2024. As of January 20, 2025, the transaction is expected to close in January 2025. Elan Corporation (TSE:6099) completed the acquisition of 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others on January 21, 2025.
お知らせ • Dec 14ELAN Corporation Announces CEO Changes, Effective March 21, 2025ELAN Corporation announced that it has resolved, at a meeting of the Board of Directors held on December 13, 2024, to change the Company's CEO. Hideharu Sakurai is scheduled to retire as CEO and Tomohiro Minezaki, the current COO, will succeed him as CEO. Scheduled date of assuming office is March 21, 2025.
お知らせ • Dec 10Elan Corporation to Report Fiscal Year 2024 Results on Feb 10, 2025Elan Corporation announced that they will report fiscal year 2024 results on Feb 10, 2025
Reported Earnings • Nov 08Third quarter 2024 earnings released: EPS: JP¥8.39 (vs JP¥10.50 in 3Q 2023)Third quarter 2024 results: EPS: JP¥8.39 (down from JP¥10.50 in 3Q 2023). Revenue: JP¥12.0b (up 13% from 3Q 2023). Net income: JP¥507.2m (down 20% from 3Q 2023). Profit margin: 4.2% (down from 6.0% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Sep 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €5.95, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 14x in the Healthcare industry in Germany. Total loss to shareholders of 36% over the past three years.
Reported Earnings • Aug 09Second quarter 2024 earnings released: EPS: JP¥9.91 (vs JP¥9.23 in 2Q 2023)Second quarter 2024 results: EPS: JP¥9.91 (up from JP¥9.23 in 2Q 2023). Revenue: JP¥11.4b (up 14% from 2Q 2023). Net income: JP¥599.0m (up 7.3% from 2Q 2023). Profit margin: 5.3% (down from 5.6% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Declared Dividend • Aug 08Dividend of JP¥14.00 announcedShareholders will receive a dividend of JP¥14.00. Ex-date: 27th December 2024 Payment date: 25th March 2025 Dividend yield will be 290%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is covered by both earnings (31% earnings payout ratio) and cash flows (53% cash payout ratio). The dividend has increased by an average of 32% per year over the past 7 years and payments have been stable during that time. EPS is expected to grow by 67% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Jun 02Elan Corporation to Report Q2, 2024 Results on Aug 06, 2024Elan Corporation announced that they will report Q2, 2024 results on Aug 06, 2024
Reported Earnings • May 09First quarter 2024 earnings released: EPS: JP¥12.01 (vs JP¥11.50 in 1Q 2023)First quarter 2024 results: EPS: JP¥12.01 (up from JP¥11.50 in 1Q 2023). Revenue: JP¥11.5b (up 17% from 1Q 2023). Net income: JP¥726.0m (up 4.5% from 1Q 2023). Profit margin: 6.3% (down from 7.1% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 27Full year 2023 earnings released: EPS: JP¥41.65 (vs JP¥34.44 in FY 2022)Full year 2023 results: EPS: JP¥41.65 (up from JP¥34.44 in FY 2022). Revenue: JP¥41.4b (up 14% from FY 2022). Net income: JP¥2.52b (up 21% from FY 2022). Profit margin: 6.1% (up from 5.7% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
お知らせ • Mar 22Elan Corporation (TSE:6099) agreed to acquire 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others for VND220 billion.Elan Corporation (TSE:6099) agreed to acquire 51% stake in Tmc Viet Nam Trading And Service Company Limited from Nguyen Thi Thanh and others for VND220 billion on March 22, 2024. The transaction is expected to close in mid June 2024.
お知らせ • Feb 24Elan Corporation to Report Q1, 2024 Results on May 08, 2024Elan Corporation announced that they will report Q1, 2024 results on May 08, 2024
Reported Earnings • Feb 16Full year 2023 earnings released: EPS: JP¥41.65 (vs JP¥34.44 in FY 2022)Full year 2023 results: EPS: JP¥41.65 (up from JP¥34.44 in FY 2022). Revenue: JP¥41.4b (up 14% from FY 2022). Net income: JP¥2.52b (up 21% from FY 2022). Profit margin: 6.1% (up from 5.7% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
お知らせ • Feb 15Elan Corporation, Annual General Meeting, Mar 22, 2024Elan Corporation, Annual General Meeting, Mar 22, 2024.
Upcoming Dividend • Dec 21Upcoming dividend of JP¥12.00 per share at 1.1% yieldEligible shareholders must have bought the stock before 28 December 2023. Payment date: 27 March 2024. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (3.2%).
お知らせ • Dec 05Elan Corporation to Report Fiscal Year 2023 Results on Feb 14, 2024Elan Corporation announced that they will report fiscal year 2023 results on Feb 14, 2024
Reported Earnings • Nov 08Third quarter 2023 earnings released: EPS: JP¥10.50 (vs JP¥9.69 in 3Q 2022)Third quarter 2023 results: EPS: JP¥10.50 (up from JP¥9.69 in 3Q 2022). Revenue: JP¥10.6b (up 16% from 3Q 2022). Net income: JP¥635.0m (up 8.4% from 3Q 2022). Profit margin: 6.0% (down from 6.4% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 1.3% decline forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
お知らせ • Aug 30Elan Corporation to Report Q3, 2023 Results on Nov 07, 2023Elan Corporation announced that they will report Q3, 2023 results on Nov 07, 2023
New Risk • Aug 11New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
お知らせ • Aug 09Elan Corporation Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2023Elan Corporation provided consolidated earnings guidance for the full year ending December 31, 2023. For the year, the company expects net sales of ¥43,700 million, operating profit of ¥3,600 million, profit attributable to owners of parent of ¥2,500 million, and earnings per share of ¥41.35.
Reported Earnings • Aug 08Second quarter 2023 earnings released: EPS: JP¥9.23 (vs JP¥9.11 in 2Q 2022)Second quarter 2023 results: EPS: JP¥9.23 (up from JP¥9.11 in 2Q 2022). Revenue: JP¥9.92b (up 13% from 2Q 2022). Net income: JP¥558.0m (up 1.3% from 2Q 2022). Profit margin: 5.6% (down from 6.3% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Jun 28Elan Corporation to Report Q2, 2023 Results on Aug 07, 2023Elan Corporation announced that they will report Q2, 2023 results on Aug 07, 2023
Reported Earnings • May 12First quarter 2023 earnings released: EPS: JP¥11.50 (vs JP¥10.35 in 1Q 2022)First quarter 2023 results: EPS: JP¥11.50 (up from JP¥10.35 in 1Q 2022). Revenue: JP¥9.86b (up 12% from 1Q 2022). Net income: JP¥695.0m (up 11% from 1Q 2022). Profit margin: 7.1% (in line with 1Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • May 12+ 1 more updateElan Corporation Provides Consolidated Earnings Guidance for the Six Month Ending June 30, 2023 and Full Year Ending December 31, 2023Elan Corporation provided consolidated earnings guidance for the six month ending June 30, 2023 and full year ending December 31, 2023. For the six months, the company expects net sales of ¥20,300 million, operating profit of ¥1,730 million, profit attributable to owners of parent of ¥1,200 million, and earnings per share of ¥19.85.For the year, the company expects net sales of ¥43,700 million, operating profit of ¥3,600 million, profit attributable to owners of parent of ¥2,500 million, and earnings per share of ¥41.35.
Reported Earnings • Mar 30Full year 2022 earnings released: EPS: JP¥34.44 (vs JP¥31.48 in FY 2021)Full year 2022 results: EPS: JP¥34.44 (up from JP¥31.48 in FY 2021). Revenue: JP¥36.3b (up 15% from FY 2021). Net income: JP¥2.08b (up 9.3% from FY 2021). Profit margin: 5.7% (down from 6.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 12Full year 2022 earnings released: EPS: JP¥34.44 (vs JP¥31.48 in FY 2021)Full year 2022 results: EPS: JP¥34.44 (up from JP¥31.48 in FY 2021). Revenue: JP¥36.3b (up 15% from FY 2021). Net income: JP¥2.08b (up 9.3% from FY 2021). Profit margin: 5.7% (down from 6.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Feb 10+ 2 more updatesElan Corporation, Annual General Meeting, Mar 24, 2023Elan Corporation, Annual General Meeting, Mar 24, 2023.
お知らせ • Dec 28Elan Corporation to Report Fiscal Year 2022 Results on Feb 09, 2023Elan Corporation announced that they will report fiscal year 2022 results on Feb 09, 2023
Upcoming Dividend • Dec 22Upcoming dividend of JP¥10.00 per shareEligible shareholders must have bought the stock before 29 December 2022. Payment date: 24 March 2023. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (4.0%).
Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 7 non-independent directors. Outside Independent Director Nobuyuki Takagi was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Nov 12Third quarter 2022 earnings released: EPS: JP¥9.69 (vs JP¥8.70 in 3Q 2021)Third quarter 2022 results: EPS: JP¥9.69 (up from JP¥8.70 in 3Q 2021). Revenue: JP¥9.16b (up 14% from 3Q 2021). Net income: JP¥586.0m (up 11% from 3Q 2021). Profit margin: 6.4% (down from 6.5% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 12+ 1 more updateElan Corporation Provides Consolidated Earning Guidance for the Year Ending December 31, 2022Elan Corporation provided consolidated earning guidance for the year ending December 31, 2022. For the period, the company expected net sales to be JPY 37,000 million, operating profit to be JPY 3,000 million, ordinary profit to be JPY 3,020 million, profit attributable to owners of parent to be JPY 2,000 million and earnings per share to be JPY 33.08.
お知らせ • Aug 31Elan Corporation to Report Q3, 2022 Results on Nov 10, 2022Elan Corporation announced that they will report Q3, 2022 results on Nov 10, 2022
お知らせ • Aug 16+ 1 more updateElan Corporation Provides Earnings Guidance for the Year Ending December 31, 2022Elan Corporation provided earning guidance for the year ending December 31, 2022. For the period, the company expects net sales of JPY 37,000 million, operating profit of JPY 3,000 million, ordinary profit of JPY 3,020 million, profit attributable to owners of parent of JPY 2,000 million and earnings per share JPY 33.08.
Reported Earnings • Aug 12Second quarter 2022 earnings released: EPS: JP¥9.11 (vs JP¥7.42 in 2Q 2021)Second quarter 2022 results: EPS: JP¥9.11 (up from JP¥7.42 in 2Q 2021). Revenue: JP¥8.81b (up 14% from 2Q 2021). Net income: JP¥551.0m (up 23% from 2Q 2021). Profit margin: 6.3% (up from 5.8% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 2.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
お知らせ • May 29Elan Corporation to Report Q2, 2022 Results on Aug 10, 2022Elan Corporation announced that they will report Q2, 2022 results on Aug 10, 2022
お知らせ • May 16+ 1 more updateElan Corporation Provides Dividend Guidance for the Year Ending December 31, 2022Elan Corporation provided dividend guidance for the year ending December 31, 2022. For the year, the company expects to pay dividend of JPY 10.00 per share.
Reported Earnings • May 15First quarter 2022 earnings released: EPS: JP¥10.35 (vs JP¥8.37 in 1Q 2021)First quarter 2022 results: EPS: JP¥10.35 (up from JP¥8.37 in 1Q 2021). Revenue: JP¥8.79b (up 17% from 1Q 2021). Net income: JP¥626.0m (up 24% from 1Q 2021). Profit margin: 7.1% (up from 6.7% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 16%, compared to a 5.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Board Change • Apr 28No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 5 highly experienced directors. No independent directors (8 non-independent directors). VP & Director Yoshiteru Ando was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 08Elan Corporation to Report Q1, 2022 Results on May 12, 2022Elan Corporation announced that they will report Q1, 2022 results on May 12, 2022
お知らせ • Feb 16Elan Corporation Provides Consolidated Earnings Guidance for the Six Months Ending June 30, 2022 and Year Ending December 31, 2022Elan Corporation provided consolidated earnings guidance for the six months ending June 30, 2022 and Year Ending December 31, 2022. For the period, the company expects net sales of JPY 17,300 million, operating profit of JPY 1,430 million, profit attributable to owners of parent of JPY 980 million and earnings per share of JPY 16.21.For the year, the company expects net sales of JPY 37,000 million, operating profit of JPY 3,000 million, profit attributable to owners of parent of JPY 2,000 million and earnings per share of JPY 33.08.
お知らせ • Feb 15+ 1 more updateElan Corporation Announces Dividend for the Year Ended December 31, 2021, Payable on March 24, 2022Elan Corporation announced dividend for the year ended December 31, 2021. For the year, the company announced to pay dividend of JPY 9.00 per share compared to JPY 14 per share paid a year ago. Scheduled date to commence dividend payments: March 24, 2022.
お知らせ • Feb 12Elan Corporation, Annual General Meeting, Mar 23, 2022Elan Corporation, Annual General Meeting, Mar 23, 2022.
Reported Earnings • Feb 11Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: JP¥31.48 (up from JP¥23.86 in FY 2020). Revenue: JP¥31.6b (up 21% from FY 2020). Net income: JP¥1.91b (up 32% from FY 2020). Profit margin: 6.0% (up from 5.5% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 19%, compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
Buying Opportunity • Jan 17Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 17%. The fair value is estimated to be JP¥9.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% per annum over the last 3 years. Earnings per share has grown by 28% per annum over the last 3 years.
Upcoming Dividend • Dec 22Upcoming dividend of JP¥8.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 24 March 2022. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (2.6%).
Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS JP¥8.70 (vs JP¥6.24 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥8.06b (up 21% from 3Q 2020). Net income: JP¥526.0m (up 39% from 3Q 2020). Profit margin: 6.5% (up from 5.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 13Elan Corporation Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021Elan Corporation provided consolidated earnings guidance for the year ending December 31, 2021. For the year, the company expects net sales of JPY 31,000 million, operating profit of JPY 2,500 million, profit attributable to owners of parent of JPY 1,680 million and earnings per share of JPY 27.72.
お知らせ • May 17+ 1 more updateElan Corporation Provides Earnings Guidance for the Six Months and Year Ending December 31, 2021Elan Corporation provided earnings guidance for the six months and year ending December 31, 2021. For the six months, the company expected Net sales of JPY 15,100 Million, Operating profit of JPY 1,300 Million, Profit attributable to owners of parent of JPY 900 Million and Earnings per share of JPY 14.85. For the year, the company expected Net sales of JPY 31,000 Million, Operating profit of JPY 2,500 Million, Profit attributable to owners of parent of JPY 1,680 Million and Earnings per share of JPY 27.72.
Reported Earnings • May 15First quarter 2021 earnings released: EPS JP¥8.37 (vs JP¥5.61 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: JP¥7.52b (up 26% from 1Q 2020). Net income: JP¥507.0m (up 49% from 1Q 2020). Profit margin: 6.7% (up from 5.7% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Mar 30Full year 2020 earnings released: EPS JP¥47.72 (vs JP¥16.32 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: JP¥26.1b (up 21% from FY 2019). Net income: JP¥1.45b (up 46% from FY 2019). Profit margin: 5.5% (up from 4.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year whereas the company’s share price has increased by 40% per year.
Is New 90 Day High Low • Feb 20New 90-day low: €10.60The company is down 11% from its price of €11.90 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.35 per share.
お知らせ • Feb 14Elan Corporation, Annual General Meeting, Mar 23, 2021Elan Corporation, Annual General Meeting, Mar 23, 2021.
Reported Earnings • Feb 14Full year 2020 earnings released: EPS JP¥47.72 (vs JP¥16.32 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: JP¥26.1b (up 21% from FY 2019). Net income: JP¥1.45b (up 46% from FY 2019). Profit margin: 5.5% (up from 4.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.
Analyst Estimate Surprise Post Earnings • Feb 14Revenue beats expectationsRevenue exceeded analyst estimates by 3.0%. Over the next year, revenue is forecast to grow 14%, compared to a 3.4% growth forecast for the Healthcare industry in Germany.
お知らせ • Jan 07Elan Corporation to Report Fiscal Year 2020 Results on Feb 12, 2021Elan Corporation announced that they will report fiscal year 2020 results on Feb 12, 2021
Upcoming Dividend • Dec 22Upcoming Dividend of JP¥12.00 Per ShareWill be paid on the 26th of March to those who are registered shareholders by the 29th of December. The trailing yield of 0.4% is below the top quartile of German dividend payers (3.5%), and is lower than industry peers (2.1%).
Reported Earnings • Nov 19Third quarter 2020 earnings released: EPS JP¥12.48The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: JP¥6.69b (up 23% from 3Q 2019). Net income: JP¥378.0m (up 62% from 3Q 2019). Profit margin: 5.6% (up from 4.3% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.
Analyst Estimate Surprise Post Earnings • Nov 19Revenue beats expectationsRevenue exceeded analyst estimates by 6.2%. Over the next year, revenue is forecast to grow 14%, compared to a 4.2% growth forecast for the Healthcare industry in Germany.
Is New 90 Day High Low • Nov 16New 90-day high: €22.60The company is up 21% from its price of €18.70 on 18 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.46 per share.
Analyst Estimate Surprise Post Earnings • Nov 14Revenue beats expectationsRevenue exceeded analyst estimates by 6.2%. Over the next year, revenue is forecast to grow 13%, compared to a 4.3% growth forecast for the Healthcare industry in Germany.
Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS JP¥12.48The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: JP¥6.69b (up 23% from 3Q 2019). Net income: JP¥378.0m (up 62% from 3Q 2019). Profit margin: 5.6% (up from 4.3% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Sep 28New 90-day high: €20.60The company is up 35% from its price of €15.30 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.13 per share.
お知らせ • Sep 11Elan Corporation to Report Q3, 2020 Results on Nov 12, 2020Elan Corporation announced that they will report Q3, 2020 results on Nov 12, 2020
